William Stenger Sentenced to 18 months in Prison in Connection with the AnC Vermont EB-5 Project in the Northeast Kingdom
For Immediate Release
U.S. Attorney's Office, District of Vermont
The Press Release has been updated to detail the name of the FDA Office of Criminal Investigations.
The United States Attorney’s Office announced that William Stenger, 73, of Newport, Vermont, was sentenced today to 18 months in prison by Chief Judge Geoffrey W. Crawford in United States District Court. Chief Judge Crawford also ordered a 3-year term of supervised release and ordered Stenger to pay $250,000 in restitution. Today’s sentencing follows Stenger’s August 2021 guilty plea to a felony count of knowingly and willfully submitting false documents to the Vermont Regional Center (“VRC”) in connection with his involvement in the Jay Peak Biomedical Research Park EB-5 investment project, also called the AnC Vermont project.
According to court records and proceedings, the AnC Vermont project was designed to raise $110 million from 220 immigrant investors in order to construct and operate a biotechnology facility in Newport, Vermont. EB-5 immigrant investors could qualify for permanent resident status (commonly known as a green card) by investing $500,000 in a commercial enterprise approved by the VRC, which had the authority to approve and monitor EB-5 projects in Vermont, and by USCIS. In order to obtain a green card, each investor needed to demonstrate to USCIS that his or her investment had created, or would create within a few years, ten jobs. So, for the AnC Vermont project, it was necessary for Stenger and his co-defendants to demonstrate a plan to create at least 2,200 jobs in a short timeframe in order to obtain USCIS approval. From 2012 to 2016, approximately 169 investors invested approximately $85 million in the AnC Vermont project, in addition to paying approximately $8 million in “administrative fees.” Fundraising was never completed, and the AnC Vermont facility was never constructed.
Stenger pleaded guilty to submitting false documents to the VRC in January of 2015 as part of his effort to convince the VRC to allow him to continue marketing the AnC Vermont project. As Stenger admitted during his change of plea hearing, due to VRC’s concerns about a number of aspects of the AnC project, Stenger had agreed with the VRC in late June 2014 to suspend offering and marketing of the project. Stenger knew that he had to provide answers to questions from VRC about the project’s financial projections and about the status of U.S. Food and Drug Administration (“FDA”) approvals needed for commercialization of the products in order to be permitted to market the project again. Stenger’s January 2015 submission addressed, among other things, these topics. Both the financial projections and the FDA timeline impacted whether the project would create the number of jobs needed for the investors to obtain immigration benefits.
The AnC Vermont fraud involved two aspects: the defendants’ misrepresentations about job creation and future revenues, and the defendants’ misuse of investor funds. Stenger’s guilty plea centered on the misrepresentation aspect of the fraud. In connection with his sentencing, Stenger agreed not to dispute a broader set of facts asserted by the government in a sentencing-related brief, including that he participated in the misuse of investor funds along with co-defendants Ariel Quiros and William Kelly. Their misuse of funds was principally caused by debts and cost overruns on earlier EB-5 projects, for which Stenger bore significant responsibility. Stenger was the general partner for the EB-5 projects and assumed responsibility for how investors’ funds were used. While Stenger was not principally responsible for executing the misuse of investor funds, he knew about and assisted in it. Stenger hid the projects’ financial problems from the VRC, U.S. Citizenship and Immigration Services (USCIS), and investors, and he repeatedly abused his position of trust to assure regulators and investors that the projects were successful, and nothing was wrong.
Co-defendant William Kelly pleaded guilty to wire fraud conspiracy and concealment charges in July 2021. His sentencing hearing is scheduled to occur before Chief Judge Crawford on April 20, 2022. Co-defendant Ariel Quiros pleaded guilty to wire fraud conspiracy, money laundering, and concealment charges in August 2020. His sentencing is scheduled to occur before Chief Judge Crawford on April 29, 2022. Both Quiros and Kelly agreed to cooperate in the government’s ongoing matters. Co-defendant Choi remains at large.
Nikolas P. Kerest, United States Attorney, expresses his gratitude for the outstanding investigation assistance by the Federal Bureau of Investigation, IRS Criminal Investigation, the FDA Office of Criminal Investigations, and for the assistance of the Justice Department’s Fraud Section and Office of International Affairs. The prosecutors handling the case are Assistant U.S. Attorneys Nicole Cate and Paul Van de Graaf. William Stenger is represented by Brooks McArthur, Esq. and David Williams, Esq. Ariel Quiros is represented by Neil Taylor, Esq. and Robert Katims, Esq. William Kelly is represented by Robert Goldstein, Esq. and Mary Kehoe, Esq.
Updated April 15, 2022